Cheelcare Announces First Quarter Fiscal 2027 Financial Results

A July private placement raised $3.02 million in gross proceeds, and outstanding bank loans were repaid after quarter-end.

Rhea-AI Summary

Cheelcare (CHCRF) reported higher revenue and a smaller net loss for its fiscal first quarter ended July 31, 2026.

Revenue rose approximately 98% to CAD $828,516 from $417,981 a year earlier. Gross profit was $481,637, compared with $212,787, and gross margin was 58.1%, up from 50.9%. Net loss narrowed to $501,008, or $0.02 per share, from $1,630,108, or $0.15 per share. The prior-year quarter included a listing expense related to a reverse takeover.

Cash was $2.4 million at July 31, compared with $163,416 at April 30. A $3.02 million gross-proceeds private placement closed July 3, and outstanding Business Development Bank of Canada loans were repaid after quarter-end. A Canadian patent covering Companion technology was granted in May. Companion received U.S. Medicare and Medicaid reimbursement eligibility in January 2026. Curio engineering and validation continued toward a future Ontario resubmission, alongside the U.S. FDA 510(k) process.

Positive

• Revenue rose approximately 98% year over year to CAD $828,516
• Gross margin reached 58.1%, versus 50.9% a year earlier
• Net loss narrowed to $501,008 from $1,630,108 a year earlier
• Cash reached $2.4 million, versus $163,416 at April 30

Negative

• None.

News Explained

The completed private placement was a sale of securities that brought CAD $3.02 million in gross proceeds; the release gives no securities count or terms, so any ownership dilution cannot be sized from this disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Markham, Ontario--(Newsfile Corp. - September 25, 2026) - Cheelcare Inc. (TSXV: CHER) (OTC: CHCRF) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, today announced its financial results for the three months ended July 31, 2026. All figures are in CAD unless otherwise noted.

Operational Highlights (Three Months Ended July 31, 2026)

• Companion reimbursement and market access: The Company continued to advance Companion's U.S. commercialization following PDAC verification and Medicare and Medicaid reimbursement eligibility received in January 2026, with increased engagement across its dealer, clinician and funding networks.
• Canadian patent issued for Companion platform: In May 2026, the Canadian Intellectual Property Office granted Canadian Patent No. 3,090,535 covering core technologies underlying the Companion power-assist platform. The patent complements the Company's existing U.S. patent protection and provides additional intellectual property protection for Companion in North America.
• $3.02 million private placement completed: On July 3, 2026, Cheelcare completed an upsized private placement for gross proceeds of $3.02 million, providing additional capital to support commercialization, product development and working capital.
• Curio engineering and regulatory work continued: Cheelcare continued engineering and validation activities for Curio in support of a future resubmission under Ontario's Assistive Devices Program and continued to advance the U.S. FDA 510(k) process. Cybersecurity testing for Curio has been completed.
• Numotion Commercial Growth Summit: Subsequent to quarter-end, Cheelcare participated in Numotion's Commercial Growth Summit in Denver, presenting Companion to clinicians, Assistive Technology Professionals and other decision-makers within one of North America's largest Complex Rehab Technology networks.

First Quarter Financial Highlights (Three Months Ended July 31, 2026)

• Revenue of $828,516, compared to $417,981 in Q1 fiscal 2026, representing an increase of approximately 98%.
• Gross profit of $481,637, representing a gross margin of 58.1%, compared to a gross profit of $212,787 and a gross margin of 50.9% in Q1 fiscal 2026.
• Net loss of $501,008, or $0.02 per share, compared to a net loss of $1,630,108, or $0.15 per share, in Q1 fiscal 2026. The prior-year period included a significant listing expense associated with the Company's reverse takeover.
• Cash and cash equivalents of $2.4 million at July 31, 2026, compared with $163,416 at April 30, 2026.

Subsequent to quarter-end, the Company repaid its outstanding bank loans with the Business Development Bank of Canada in full.

"Q1 is the first full quarter where we are beginning to see the commercial impact of Companion's Medicare and Medicaid reimbursement eligibility in the United States, which was received in January 2026," said Eugene Cherny, CEO of Cheelcare. "That expanded access, together with the growth of our dealer and clinician network, is creating more opportunities to put Companion in the hands of users who can benefit from it. Our focus now is on converting that broader reimbursement access and distribution footprint into sustained Companion growth, continuing to improve manufacturing efficiency as volumes increase, and advancing Curio through the engineering, validation and regulatory work required for broader commercialization."

About Cheelcare Inc.
Cheelcare designs and manufactures innovative mobility solutions that empower independence for people with disabilities. From the Companion power assist devices to the groundbreaking Curio robotic complex-rehab power wheelchair, Cheelcare combines engineering excellence with human-centered design to improve quality of life. For more information, please visit: www.cheelcare.ca.

For further information, please contact:
Sofiya Kagan, Director of Marketing
Cheelcare Inc.
Tel: 1-888-948-2680 x 206
Email: skagan@cheelcare.com

Forward-Looking Information:
This news release may contain forward-looking statements. Forward-looking statements are based on current expectations and involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those expressed or implied. Such factors include, but are not limited to, general economic conditions, market demand, supply chain disruptions, and regulatory approvals. Any forward-looking statements are made as of the date of this news release, and the Company does not undertake to update any forward-looking statements except in accordance with applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/316019

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Cheelcare's fiscal first-quarter 2027 results?

For the quarter ended July 31, 2026, Cheelcare reported CAD $828,516 in revenue, a 58.1% gross margin and a $501,008 net loss, or $0.02 per share. Revenue was $417,981 and the net loss was $1,630,108, or $0.15 per share, in the prior-year quarter.

Has Cheelcare completed cybersecurity testing for Curio?

Yes. Cybersecurity testing for Curio has been completed.